Osteoporosis Management in Elderly Men

Initial Treatment

The American College of Physicians recommends starting oral bisphosphonates (alendronate 70 mg weekly or risedronate 35 mg weekly) as first-line pharmacologic treatment, combined with calcium (1000-1200 mg daily) and vitamin D (800-1000 IU daily) supplementation, plus a structured exercise program 1, 2, 3
Alendronate 70 mg once weekly or risedronate 35 mg once weekly are the recommended initial treatments for men with osteoporosis, reducing radiographic vertebral fractures by approximately 140 fewer per 1000 treated patients over 2-3 years 1, 2, 3

If bisphosphonates are contraindicated or cause adverse effects, use denosumab 60 mg subcutaneously every 6 months, as recommended by the American College of Rheumatology 1, 2, 3
Zoledronic acid 5 mg intravenously annually is another second-line option, particularly useful if oral medication adherence is a concern, according to the National Osteoporosis Foundation 2, 3

The National Osteoporosis Foundation recommends all men over 65 years require calcium 1000-1200 mg daily and vitamin D 800-1000 IU daily 2, 4, 3
Adequate vitamin D and calcium are necessary for bisphosphonates to work effectively, as stated by the American College of Physicians 4

Prescribe muscle resistance exercises (squats, push-ups, resistance bands) and balance exercises (heel raises, standing on one foot, tai chi), as recommended by the American Geriatrics Society 2, 3
These exercises reduce fall risk and improve bone strength independently of medication, according to the National Institute on Aging 2, 3

Use FRAX (Fracture Risk Assessment Tool) to calculate 10-year probability of hip and major osteoporotic fractures, as recommended by the National Osteoporosis Foundation 2, 3
Check serum total testosterone level as part of pre-treatment assessment, according to the Endocrine Society 6, 2, 3

Plan to reassess after 5 years of continuous bisphosphonate treatment, as recommended by the American College of Physicians 1, 4
After 5 years, consider a drug holiday unless the patient has very high fracture risk, according to the National Osteoporosis Foundation 1, 4

If the patient has a recent vertebral fracture, hip fracture with T-score ≤-2.5, or multiple fractures, consider starting with an anabolic agent (teriparatide, abaloparatide, or romosozumab) followed by bisphosphonate consolidation therapy, as recommended by the American College of Rheumatology 6, 2, 3
After completing anabolic therapy, transition to bisphosphonate to maintain gains, according to the National Osteoporosis Foundation 1, 4